• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金属放射性核素标记抗体:核素化学对剂量分布的影响。

Antibodies labeled with metallic radionuclides: influence of nuclide chemistry on dose distribution.

作者信息

Vaughan A T, Yankuba S C, Anderson P

出版信息

NCI Monogr. 1987(3):141-4.

PMID:3029601
Abstract

An antibody with human CEA specificity has been labeled with either yttrium-90, scandium-47, or indium-111, via a diethylenetriamine pentaacetic acid (DTPA) link covalently bound to the protein. The clearance of these proteins from the blood of mice can be described by a single exponential; the half-life decreases in the order indium-111 greater than yttrium-90 greater than scandium-47. Associated with the blood clearance is an uptake of radioactivity into the liver; scandium-47 has the highest concentration, indium-111 has the least, and yttrium-90 is intermediate. There is no correlation between these results and the equilibrium stability constants of the metals with DTPA-like ligands. The results obtained show that, in vivo, scandium-47 and yttrium-90 are more easily displaced from DTPA by other ions than is indium-111. They also show that free DTPA is able to extract yttrium-90 and scandium-47, but not indium-111, from the liver of treated animals, indicating that indium-111 is resistant to ligand exchange reactions in vivo. These data indicate that 1) the equilibrium stability constant is not a good indicator of the in vivo stability of metal-labeled proteins and 2) it is possible to manipulate the ion distribution and therefore the dose from scandium-47 and yttrium-90 after injection of the labeled proteins.

摘要

一种具有人癌胚抗原(CEA)特异性的抗体已通过与蛋白质共价结合的二亚乙基三胺五乙酸(DTPA)连接体,用钇 - 90、钪 - 47或铟 - 111进行了标记。这些蛋白质从小鼠血液中的清除情况可用单指数函数来描述;半衰期按铟 - 111大于钇 - 90大于钪 - 47的顺序递减。与血液清除相关的是放射性在肝脏中的摄取;钪 - 47的浓度最高,铟 - 111最低,钇 - 90居中。这些结果与金属与类DTPA配体的平衡稳定常数之间没有相关性。所获得的结果表明,在体内,钪 - 47和钇 - 90比铟 - 111更容易被其他离子从DTPA中置换出来。它们还表明,游离的DTPA能够从经处理动物的肝脏中提取钇 - 90和钪 - 47,但不能提取铟 - 111,这表明铟 - 111在体内对配体交换反应具有抗性。这些数据表明:1)平衡稳定常数并非金属标记蛋白质体内稳定性的良好指标;2)在注射标记蛋白质后,有可能操控离子分布,进而操控来自钪 - 47和钇 - 90的剂量。

相似文献

1
Antibodies labeled with metallic radionuclides: influence of nuclide chemistry on dose distribution.金属放射性核素标记抗体:核素化学对剂量分布的影响。
NCI Monogr. 1987(3):141-4.
2
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.铟-111标记的嵌合抗癌胚抗原单克隆抗体的临床评估
J Nucl Med. 1997 Dec;38(12):1951-9.
3
Stability, targeting, and biodistribution of scandium-46- and gallium-67-labeled monoclonal antibody in erythroleukemic mice.
Cancer Res. 1985 May;45(5):2154-8.
4
Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.铟-111和钇-88标记的树枝状聚合物-1B4M-DTPA的体内生物分布及其与抗Tac单克隆抗体偶联物的评估。
Bioconjug Chem. 1999 Jan-Feb;10(1):103-11. doi: 10.1021/bc980091d.
5
Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.利用生物制备的双特异性抗癌胚抗原x抗铟标记二乙三胺五乙酸抗体对表达癌胚抗原的肿瘤进行预靶向。
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7130s-7136s. doi: 10.1158/1078-0432.CCR-1004-0006.
6
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.CHX-DTPA及其他用于单克隆抗体钇标记的配体的血清稳定性和体内生物分布评估。
J Nucl Med. 1994 May;35(5):882-9.
7
DTPA-coupled antibodies labeled with yttrium-90.用钇-90标记的二乙三胺五乙酸偶联抗体。
J Nucl Med. 1985 May;26(5):503-9.
8
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.一项I期放射免疫治疗试验,评估90钇标记的抗癌胚抗原(CEA)嵌合抗体T84.66在转移性产生CEA恶性肿瘤患者中的疗效。
Clin Cancer Res. 2000 Oct;6(10):3855-63.
9
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.肾细胞癌放射免疫治疗的优化:用131I、90Y、177Lu或186Re标记单克隆抗体cG250
J Nucl Med. 2004 Feb;45(2):327-37.
10
Tissue distribution of orally administered 91Y and 46Sc in mice.口服给予小鼠的91Y和46Sc在组织中的分布。
Health Phys. 1982 May;42(5):727-30.